LAS VEGAS — In this video from Clinical Trials at the Summit, Lejla Vajzovic, MD, FASRS, of Duke Eye Center, discusses tyrosine kinase inhibitors and gene therapy as different approaches for wet age-related macular degeneration.
“I do anticipate and I do believe there will be better improvements in visual acuities down the road, and we will be not only preserving vision for these patients but improving it as well,” Vajzovic told Healio.